AstraZeneca has unveiled a major new alliance with up-and-coming China’s CSPC Pharmaceuticals to discover and develop novel oral drug candidates, a collaboration which underscores the emergence of the country’s biopharma sector.
Key Takeaways
- AstraZeneca has signed a deal with China's CSPC Pharmaceuticals to use it AI drug discovery platform.
The deal announced on 13 June will see AstraZeneca pay CSPC $110m upfront to generate preclinical candidates to treat diseases...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?